# Accuracy vs. Efficiency: Benchmarking TransNeXt, MedViTV2, and RDNet for Brain Tumor MRI Classification

## ğŸ“– å°ˆæ¡ˆæ‘˜è¦ (Abstract)
æœ¬å°ˆæ¡ˆæ—¨åœ¨æ¢è¨æ·±åº¦å­¸ç¿’æ¨¡å‹åœ¨é†«ç™‚å½±åƒåˆ†æä¸­ã€Œæº–ç¢ºæ€§ã€èˆ‡ã€Œé‹ç®—æ•ˆç‡ã€çš„æ¬Šè¡¡ã€‚é‡å°è…¦ç˜¤ MRI åˆ†é¡ä»»å‹™ï¼ˆGlioma, Meningioma, Pituitary, No Tumorï¼‰ï¼Œæˆ‘å€‘æ¯”è¼ƒäº†ä¸‰ç¨®æ–°ä¸€ä»£æ¨¡å‹æ¶æ§‹ï¼š**TransNeXt**ã€**MedViTV2** èˆ‡ **RDNet**ã€‚

å¯¦é©—çµæœé¡¯ç¤ºï¼Œåœ¨è³‡æºå—é™çš„è‡¨åºŠç’°å¢ƒä¸‹ï¼Œ**RDNet-Tiny** æ˜¯æœ€ä½³é¸æ“‡ï¼Œä»¥ 86.54% çš„æº–ç¢ºåº¦èˆ‡æ¥µä½³çš„è¨“ç·´ç©©å®šæ€§å‹å‡ºã€‚ç ”ç©¶äº¦è­‰å¯¦äº†ã€Œå¤§æ¨¡å‹ä¸ä¸€å®šå¥½ã€ï¼Œéå¤§çš„åƒæ•¸é‡ï¼ˆå¦‚ RDNet-Baseï¼‰åœ¨æœ‰é™é†«ç™‚æ•¸æ“šä¸Šåè€Œå°è‡´åš´é‡çš„éæ“¬åˆèˆ‡è¨“ç·´ä¸ç©©å®šã€‚

## ğŸ—ï¸ æ¨¡å‹æ¶æ§‹ (Architectures)
æˆ‘å€‘é¸ç”¨äº†ä¸‰ç¨®ä»£è¡¨ 2024-2025 å¹´æŠ€è¡“æµæ´¾çš„æ¶æ§‹é€²è¡Œæ¯”è¼ƒï¼š

1.  **TransNeXt**: æ¨¡æ“¬äººé¡è¦–è¦ºçš„èšåˆæ³¨æ„åŠ›æ©Ÿåˆ¶ (Aggregated Attention)ï¼Œè§£æ±ºæ·±åº¦é€€åŒ–å•é¡Œ ã€‚
2.  **MedViTV2**: å°ˆç‚ºé†«å­¸å½±åƒè¨­è¨ˆï¼Œçµåˆ CNN èˆ‡ Transformer (KAN-Integrated) çš„æ··åˆæ¶æ§‹ ã€‚
3.  **Revitalized DenseNet (RDNet)**: é€éç¾ä»£åŒ–è¨­è¨ˆé‡æŒ¯ DenseNet æ½›åŠ›çš„é«˜æ•ˆæ¨¡å‹ ã€‚

## âš™ï¸ å¯¦é©—è¨­ç½® (Experimental Setup)

### è³‡æ–™è™•ç†
* **è³‡æ–™é›†**: [Kaggle Brain Tumor MRI Dataset](https://www.kaggle.com/datasets/masoudnickparvar/brain-tumor-mri-dataset)ã€‚
* **é è™•ç†**: å½±åƒèª¿æ•´ç‚º 224x224 (RDNet-Base èª¿æ•´ç‚º 384x384) ã€‚
* **è³‡æ–™å¢å¼· (Domain-Specific Augmentation)**:
    * å•Ÿç”¨ **RandAugment** (Magnitude=9) ä»¥æ¨¡æ“¬è‡¨åºŠæˆåƒå·®ç•° ã€‚
    * **é—œéµç­–ç•¥**: åˆ»æ„**åœç”¨ Mixup èˆ‡ CutMix**ã€‚å¯¦é©—ç™¼ç¾é€™äº›ç ´å£æ€§å¢å¼·æœƒç”¢ç”Ÿåƒç´ é¬¼å½±èˆ‡çµæ§‹ä¸é€£çºŒï¼Œä¸åˆ©æ–¼è…«ç˜¤é‚Šç•Œåˆ¤å®š ã€‚

### ç¡¬é«”ç’°å¢ƒ
* GPU: 2x NVIDIA GeForce RTX 2080 Ti (11GB VRAM) ã€‚
* Training Strategy: DataParallel (DP), Automatic Mixed Precision (AMP) ã€‚

## ğŸ“Š å¯¦é©—çµæœ (Results)

| Model | Max Accuracy | Training Time | Parameters/Size | Observations |
| :--- | :---: | :---: | :--- | :--- |
| **TransNeXt-Tiny** | 84.50% | 69 mins | Tiny | æ”¶æ–‚æ¥µå¿« (Early Stopping é¦–é¸)ï¼Œä½† Loss éœ‡ç›ªè¼ƒå¤§ ã€‚ |
| **MedViTV2-Small** | 82.49% | 74 mins | Small | è¡¨ç¾æœ€å·®ä¸”è¨“ç·´æœ€æ…¢ï¼Œå‡ºç¾æ˜é¡¯æ³›åŒ–å·®è· ã€‚ |
| **RDNet-Tiny** | **86.54%** | **42 mins** | Tiny | **æœ€ä½³æ¨è–¦**ã€‚è¨“ç·´æœ€å¿«ä¸” Loss æ›²ç·šæœ€å¹³æ»‘ç©©å®š ã€‚ |
| *RDNet-Base* | *88.58%* | N/A | Base | æº–ç¢ºåº¦é›–æœ€é«˜ï¼Œä½†å‡ºç¾åš´é‡å»è€¦åˆç¾è±¡ (Decoupling)ï¼Œè¨“ç·´æ¥µä¸ç©©å®šï¼Œä¸å»ºè­°è‡¨åºŠéƒ¨ç½²ã€‚ |

### é—œéµç™¼ç¾ï¼šç©©å®šæ€§ vs. æº–ç¢ºåº¦
é›–ç„¶ **RDNet-Base** åœ¨èª¿æ•´è¼¸å…¥å°ºå¯¸èˆ‡å„ªåŒ–å™¨å¾Œçªç ´è‡³ 88.58%ï¼Œä½†å…¶ Training Loss èˆ‡ Validation Loss å‡ºç¾ã€Œå»è€¦åˆç¾è±¡ã€ï¼Œé¡¯ç¤ºæ¨¡å‹å¯èƒ½æ˜¯åœ¨é€²è¡Œéš¨æ©Ÿå°é½Šè€Œéå­¸ç¿’ç©©å¥ç‰¹å¾µã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œ**RDNet-Tiny** é›–ç„¶æº–ç¢ºåº¦ç•¥ä½ 2%ï¼Œä½†å…·å‚™ç´®å¯¦çš„ç‰¹å¾µå­¸ç¿’æ›²ç·šï¼Œæ›´å…·å‚™çœŸå¯¦è‡¨åºŠéƒ¨ç½²åƒ¹å€¼ã€‚
